Armata wins FDA agreement on pediatric study plan for AP-SA02 in complicated S. aureus bacteremia
ARMP•FDA agrees to initial pediatric study plan for AP-SA02
Armata Pharmaceuticals secured FDA agreement on an initial pediatric study plan for AP-SA02 in complicated Staphylococcus aureus bacteremia.
The milestone supports a future biologics license application for AP-SA02.
Pediatric trials were deferred until adult Phase 3 data; the adult study is expected to start in H2 2026.
